China News Service, December 21. According to Euronet, as reported by Eurolink, with the continuous spread of the Omi Keron variant of the new crown virus, a survey pointed out that nearly half of Italians have given up on vacation, and more than 15% of them have given up on vacation. Cancel Christmas and New Year trips.

In addition, the vaccine developed by Novavax in the United States has become the fifth new crown vaccine authorized by the European Union for emergency use.

Data map: Turin, Italy, Italian railway staff check passengers' green passes at the station.

Covid-19 worries Italians giving up on vacation

　　According to reports, as the threat posed by the new crown virus Omi Keron mutant strains to Christmas and New Year continues to deepen, the Italian Market Research Institute issued a survey report stating that in view of people’s concerns about the new crown virus and Omi Keron, 48% Italians, about 24 million people have given up on vacation; 16% of them, about 8 million people, have cancelled their Christmas and New Year travel itineraries.

　　According to reports, at present, only 24% of people in Italy have decided to travel for Christmas and New Year, and about 90% of them choose to travel in the country.

　　The latest COVID-19 data from the Italian Ministry of Health show that the number of confirmed COVID-19 cases, hospitalized and intensive care patients in Italy is on the rise.

For this reason, major cities such as Rome and Naples in Italy have decided to cancel celebrations such as Christmas and New Year rallies.

　　The director of Italy’s National Coronavirus Emergency Response Committee, Figglioro, called on the initiative to abide by the anti-epidemic regulations during the Christmas season, actively vaccinate the third shot, and jointly respond to the threat posed by Omi Keron, and avoid holding large gatherings during the holiday season.

U.S. Novavax vaccine receives EU emergency use authorization

　　On the 20th local time, the European Medicines Agency (EMA) recommended the use of a vaccine developed by Novavax in the United States, making the vaccine the fifth new crown vaccine authorized by the European Union for emergency use.

　　However, EMA said that there are still limited data on the vaccine's effectiveness against certain variants of the new coronavirus, including Omi Keron.

After a comprehensive evaluation, the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) agreed that the vaccine's data are reliable and meet the EU's efficacy, safety and quality standards.

　　According to reports, on the 20th local time, the Italian Ministry of Civil Defense reported 16,213 new confirmed cases and 137 deaths.

(Boyuan)